Treatment recommendations for psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 9, 2009, Pages 1387-1394

  Ritchlin, C T ^a   Kavanaugh, A ^b   Gladman, D D ^c   Mease, P J ^d   Helliwell, P ^e   Boehncke, W H ^f   De Vlam, K ^g   Fiorentino, D ^h   FitzGerald, O ⁱ   Gottlieb, A B ^j   McHugh, N J ^k   Nash, P ^l   Qureshi, A A ^m   Soriano, E R ⁿ   Taylor, W J ^o  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d Seattle Rhumatology Associates   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f GOETHE UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h STANFORD UNIVERSITY   (United States)

ⁱ ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^j TUFTS MEDICAL CENTER   (United States)

^k ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^l UNIVERSITY OF QUEENSLAND   (Australia)

^m HARVARD MEDICAL SCHOOL   (United States)

ⁿ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^o UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; ETRETIN; GLUCOCORTICOID; HYDROXYUREA; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; SALAZOSULFAPYRIDINE; STEROID; TIOGUANINE; TUMOR NECROSIS FACTOR ANTIBODY;

ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DACTYLITIS; DISEASE SEVERITY; ENTHESITIS; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MUSCULOSKELETAL SYSTEM INFLAMMATION; NAIL DISEASE; PATIENT CARE; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; SKIN DISEASE; SPINE DISEASE; SYSTEMATIC REVIEW; ULTRAVIOLET B RADIATION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 69949125952     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.094946     Document Type: Article

References (40)

1. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-1421
2. Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007;156:258-262 (Pubitemid 46095952)
3. McCarey D, McInnes IB. Psoriatic arthritis: current topics. Curr Rheumatol Rep 2007;9:442-448
4. Setty AR, Choi HK. Psoriatic arthritis epidemiology. Curr Rheumatol Rep 2007;9:449-454
5. Mallbris L, Ritchlin CT, Stahle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006;8:355-363 (Pubitemid 44638828)
6. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-592
7. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-1741 (Pubitemid 44547793)
8. Ritchlin C. Psoriatic disease - from skin to bone. Nat Clin Pract Rheumatol 2007;3:698-706.
9. Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006;33:1228-1230 (Pubitemid 44025130)
10. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-1430 (Pubitemid 44025163)
11. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1431-1434 (Pubitemid 44025164)
12. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006;33:1435-1438 (Pubitemid 44025165)
13. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439-1441 (Pubitemid 44025166)
14. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-1456 (Pubitemid 44025169)
15. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447-1451 (Pubitemid 44025168)
16. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006;33:1442-1446 (Pubitemid 44025167)
17. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 1997;126:376-380
18. Thalheimer W, Cook S. How to calculate effect sizes from published research articles: a simplified methodology. http://www.work-learning.com/ effect-sizes.htm (accessed 5 May 2008).
19. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-2673 (Pubitemid 44205029)
20. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-1170 (Pubitemid 46774868)
21. Bond SJ, Farewell VT, Schentag CT, Gladman DD. Predictors for radiological damage in psoriatic arthritis: results from a single centre. Ann Rheum Dis 2007;66:370-376
22. Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373-1378 (Pubitemid 44620449)
23. Leeb BF, Andel I, Sautner J, Fassl C, Nothnagl T, Rintelen B. The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients. Arthritis Rheum 2007;57:256-260 (Pubitemid 47164087)
24. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. International spondyloarthritis interobserver reliability exercise - the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740-1745 (Pubitemid 47267619)
25. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann Rheum Dis 1998;57:135-140
26. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452
27. Marsland AM, Chalmers RJG, Hollis S, Leonardi-Bee J, Griffiths CEM. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006;1:CD001433.
28. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-2022
29. Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-231
30. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005;64:188-190
31. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol 2006;54(Suppl 2):S85-91.
32. Mease P. Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006;8:348-354 (Pubitemid 44638827)
33. Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W. Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004;50:24-35. (Pubitemid 38084284)
34. Gladman DD, Mease PJ, Healy P, Helliwell PS, Fitzgerald O, Cauli A, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2007;34:1159-1166
35. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii49-54.
36. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-824 (Pubitemid 37026490)
37. Cohen JD, Cunin P, Farrenq V, Oniankitan O, Carton L, Chevalier X, et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 2006;33:79-81. (Pubitemid 43054284)
38. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005;32:80-85 (Pubitemid 40092596)
39. Chandran V, Cook R, Helliwell P, Kavanaugh A, McHugh N, Mease P, et al. International Multi-centre Psoriasis and psoriatic Arthritis Reliability Trial (GRAPPAIMPART): Assessment of skin, joints, nails and dactylitis. Arthritis Rheum 2007;56(Suppl 9):S798.
40. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745-1750 (Pubitemid 41324815)